


# FDA WARNING LETTERS

## ANALYSIS AND GUIDANCE



Jeanne Moldenhauer

[www.pda.org/bookstore](http://www.pda.org/bookstore)

# **FDA Warning Letters**

## **Analysis and Guidance**

**Jeanne Moldenhauer**

***To order this book, please visit: [go.pda.org/FWLAG](http://go.pda.org/FWLAG)***

**PDA**  
Bethesda, MD, USA  
**DHI Publishing, LLC**  
River Grove, IL, USA

[www.pda.org/bookstore](http://www.pda.org/bookstore)

**ISBN: 978-1-942911-41-8**

**Copyright © 2020 Jeanne Moldenhauer**

**All rights reserved.**

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book. Websites cited are current at the time of publication. The author has made every effort to provide accurate citations. If there are any omissions, please contact the publisher.

While every effort has been made by the publisher and the author to ensure the accuracy of the information expressed in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the author and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.

This book is printed on sustainable resource paper approved by the Forest Stewardship Council. The printer, Gasch Printing, is a member of the Green Press Initiative and all paper used is from SFI (Sustainable Forest Initiative) certified mills.



*Connecting People, Science and Regulation®*



**PDA Global Headquarters**

Bethesda Towers, Suite 150  
4350 East-West Highway  
Bethesda, MD 20814  
United States  
[www.pda.org/bookstore](http://www.pda.org/bookstore)  
001-301-986-0293

**Davis Healthcare International Publishing, LLC**

2636 West Street  
River Grove  
IL 60171  
United States  
[www.DHIBooks.com](http://www.DHIBooks.com)

[www.pda.org/bookstore](http://www.pda.org/bookstore)

---

---

# CONTENTS

<b>About the Author</b>	<b>ix</b>
<b>I Introduction</b>	<b>I</b>
References	3
<b>2 Why can FDA Inspect my Plant?</b>	<b>5</b>
Responsibilities of the FDA	5
Review of New Products	6
Monitoring Products on the Market	6
Development of Standards and Regulations	7
Research Activities	7
Enforcement Activities	7
The Food, Drug and Cosmetic Act	8
The Bill of Rights	9
Constitutional Challenges to the Authority to Inspect Facilities	9
FDA Responsibilities	11
FDA Inspections	12
FDA Investigators	14
The FDA Investigator's Role During an Inspection	14
Regulatory Notes	14

Team Inspections	15
FDA's Inspection Preparation	16
Pre-announcements	16
Notice of Inspection	17
Follow-up Inspections Conducted via Court Order	18
Inspections when Criminal Actions are Contemplated	18
Preliminary Questions Asked	18
Inspectional Approach	18
Typical Inspection Techniques	19
Fact-Finding Mission	20
Sample Collection	21
Interview Techniques	21
Reporting Observations	22
Annotation of the FDA-483	23
Wrap-Up Meetings (Discussions with Management)	23
Establishment Investigation Report (EIR)	24
Affidavits	24
Commonly Used FDA Inspection Forms	25
Pre-Approval Inspections (PAIs)	25
Refusing an Inspection	25
References	26
<b>3 FDA's Approach to Inspections</b>	<b>29</b>
Objectives of Systems-Based Drug Inspections	30
Strategy	31
Systems for Audit During Inspection	32
Quality System	32
Facilities and Equipment System	33
Materials System	33
The Production System	33
The Packaging and Labeling System	33
The Laboratory Control System	34
Inspection Options	34
Full Inspection Option	34
Abbreviated Inspection Option	34
Selection of the Systems to be Inspected	35
Product Classes	35
Other Types of Inspections	36
Compliance Inspections	36
State of Control	36
Out-of-Control	36

References	36
Attachment I: FDA Compliance Program Guidance Manual 7356.002	37
<b>4 Evaluating Your Facility for Compliance</b>	<b>67</b>
Who Should Perform Assessments	68
Typical Assessment Procedures	68
Audit Preparation	68
During the Audit	70
Completing the Assessment	70
Assessment Report	70
Assessment Follow-Up	71
Retention of Assessment Reports	71
Example of an Audit Checklist	72
<b>5 Overview of Warning Letter Observations</b>	<b>101</b>
Subpart A—General Provisions	101
§211.1 Scope	101
§211.3 Definitions	102
Subpart B—Organization and Personnel	102
§211.22 Responsibilities of the Quality Control Unit	102
§211.25 Personnel Qualifications	149
§211.28 Personnel Responsibilities	150
§211.34 Consultants	152
Subpart C—Buildings and Facilities	152
§211.42 Design and Construction Features	152
§211.44 Lighting	168
§211.46 Ventilation, air filtration, air heating and cooling	168
§211.48 Plumbing	170
§211.50 Sewage and refuse	172
§211.52 Washing and toilet facilities	172
§211.56 Sanitation	173
§211.58 Maintenance	176
Subpart D—Equipment	178
§211.63 Equipment design, size and location	178
§211.65 Equipment construction	182
§211.67 Equipment Cleaning and Maintenance	183
§211.68 Automatic, mechanical and electronic equipment	198
§211.72 Filters	219

Subpart E—Control of Components and Drug Product	
Containers and Closures	220
§211.80 General requirements	220
§211.82 Receipt and storage of untested components, drug product containers, and closures	221
§211.84 Testing and Approval or Rejection of Components, Drug Product Containers, and Closures	222
§211.86 Use of approved components, drug product containers and closures	238
§211.87 Retesting of approved components, drug product containers, and closures	238
§211.89 Rejected components, drug product containers and closures	238
§211.94 Drug product containers and closures	239
Subpart F—Production and Process Controls	240
§211.100 Written Procedures; Deviations	240
§211.101 Charge-in of components	260
§211.103 Calculation of yield	262
§211.105 Equipment identification	262
§211.110 Sampling and testing of in-process materials and drug products	263
§211.111 Time limitations on production	267
§211.113 Control of microbiological contamination	269
§211.115 Reprocessing	282
Subpart G—Packaging and Labeling Control (CFR, 2019)	283
§211.122 Materials examination and criteria	283
§211.125 Labeling issuance	285
§211.130 Packaging and labeling operations	286
§211.132 Tamper-evident packaging requirements for over-the-counter (OTC) human drug products	287
§211.134 Drug product inspection	290
§211.137 Expiration Dating	291
Subpart H—Holding and Distribution	296
§211.142 Warehousing procedures	296
§211.150 Distribution procedures	297
Subpart I—Laboratory Controls	297
§211.160 General Requirements	297
§211.165 Testing and Release for Distribution	318
§211.166 Stability Testing	349
§211.167 Special testing requirements	359
§211.170 Reserve samples	360

§211.173 Laboratory animals	362
§211.176 Penicillin contamination	362
§211.180 General requirements	363
§211.182 Equipment cleaning and use log	366
§211.184 Component, drug product container, closure, and labeling records	367
§211.186 Master production and control records	368
§211.188 Batch production and control records	371
§211.192 Production Record Review	382
§211.194 Laboratory Records	435
§211.198 Complaint files	452
§212.30 What requirements must my facilities and equipment meet?	456
Other Observations	458
General Comments	462
Access to information during inspection (Limiting Photography)	462
Additional API CGMP guidance	468
Additional guidance on aseptic processing	468
Aseptic processing consultant recommended	468
CGMP Consultant Recommended	468
Data Integrity Remediation	469
Inadequate Control of Manufacturing Processes	469
Labeling and Formulation Concerns	469
Out-of-Specification Test Results	470
Owner's Responsibilities	470
Process Controls	470
Process Validation	471
Purchase/Shipping of drugs from a manufacturer on FDA Import Alert 66-40	471
Quality Agreement	471
Quality Systems	472
Testing for Glycerin	472
Responsibilities as a Contractor	472
Unkept Facility	472
Repeat Violations at Multiple Sites	473
Receipt of Adulterated Drugs from Contract Manufacturers and Suppliers	473
Use of Bureau Veritas to Conduct Testing of Drug Products	475
Use of Contract Manufacturers	476
References	476



<b>6</b>	<b>Analysis of Warning Letters</b>	<b>499</b>
	Introduction	499
	A Focus in 2016 – Data Integrity and Data Governance	500
	A Focus in 2016 – The Quality Department’s Responsibilities	503
	A Focus in 2017 – Data Integrity	504
	A Focus on Quality – 2018	505
	A Focus on Stability – 2019	506
	A Focus on Quality – 2019	507
	Observations Trended for the Past Four Years	508
	Conclusion	513
	References	513
 <b>7</b>	 <b>Avoiding and Responding to Warning Letters</b>	 <b>515</b>
	Introduction	515
	A Warning Letter has been Issued – Now What?	516
	Preparing Official Warning Letter Responses	519
	There are Observations that my Company Believes are Incorrect	521
	Close-Out of the Warning Letter	523
	Conclusion	524
	References	524
 <b>Appendix 1:</b>	 <b>The Top 10 FDA 483s from FY 2019</b>	 <b>527</b>
 <b>Appendix 2:</b>	 <b>Typical Pre-Inspection Expectations from an FDA Inspector</b>	 <b>533</b>
 <b>Index</b>		 <b>543</b>